I was not happy about the offering. It suggests they are having troubles partnering IL-21.
If this were a biotech with no track record of partnering effectively I might agree. But given their track record I would assume that they are just living up to their stated mission objective, which is to keep things in house long enough to maximize the value.
Market Data 
Markets 
AI
